(HealthDay)—Admelog (insulin lispro), a short-acting form of insulin, has been approved by the U.S. Food and Drug Administration to treat patients aged 3 years and older with either type of diabetes. Admelog is the first drug approved as a follow-up product based on an abbreviated new process dubbed 505(b)(2), the agency said Monday in a news release....